Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Jul;33(4):267–273. doi: 10.1007/BF01744947

Immunogenicity of a non-class I MHC expressing murine tumor transfected with the influenza virus hemagglutinin or murine interleukin-2 genes

Toshiyuki Itaya 1, Eric Fearon 2, Troy Fiesinger 1, Barbara Hunt 1, Bert Vogelstein 2, Philip Frost 1,3,✉
PMCID: PMC11038502  PMID: 1905583

Abstract

The transfection of murine SP1 tumor cells with the hemagglutinin (HA) gene of influenza virus results, after fluorescent-activated cell sorting (FACS), in the selection of high-HA-expressing cell lines called H4A and H4B. Both lines fail to grow in syngeneic animals at doses that result in 100% tumor take of non-transfected tumor cells. Both grow in immunosuppressed mice. SP1 and H4A or H4B cells express few class I major histocompatibility complex (MHC) antigens but do express class II IAk antigens. H4A or H4B cells engender a cytotoxic T lymphocyte (CTL) response but cannot protect against a challenge with SP1 cells. This CTL response is inhibited by anti-CD4 but not anti-CD8 antibodies. Using FACS, we were able to select a population (called H5AK5) with high class-I MHC antigen expression. Like H4A and H4B, H5AK5 cells fail to grow in syngeneic animals but do grow in immunosuppressed mice. However, unlike H4A or H4B, H5AK5 can induce protection against a challenge with 1 × 105 SP1 cells. These studies indicate that the immunogenicity ofHA-transfected SP1 cells may correlate with the cell-surface expression of class II MHC antigens. However, HA-expressing SP1 cells seem able to induce a protective response against a parent SP1 cell challenge only if they also express class I MHC antigens. This view is supported by the observations that SP1 cells expressing murine interleukin-2 do not express class I MHC antigens, fail to grow in syngeneic animals, do grow in immunosuppressed mice but do not protect against a challenge with parental SP1 cells.

Key words: Major histocompatibility complex, Transfected genes, Immunogenicity, Hemagglutinin

Footnotes

This work was supported by The Clayton Fund, The Sid W. Richardson Foundation and PHS grants CA 39853 and 41525. Toshiyuki Itaya is a visiting scientist supported by the Smith Education Fund of the Department of Cell Biology. Troy Fiesinger is a summer research investigator sponsored by The University of Texas M. D. Anderson Cancer Center Summer Program for College Students

References

  • 1.Carlow DA, Kerbel RS, Feltis JT, Elliott BE. Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. J Natl Cancer Inst. 1985;75:291. [PubMed] [Google Scholar]
  • 2.Carlow DA, Kerbel RS, Elliott BE. Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma. J Natl Cancer Inst. 1989;81:759. doi: 10.1093/jnci/81.10.759. [DOI] [PubMed] [Google Scholar]
  • 3.Elliott BE, Carlow DA, Ivimey L, Arnold M, Hampton N, Bosman P. In situ augmentation of class I major histocompatibility antigen expression on immunogenic variants of a spontaneous murine mammary carcinoma. Cancer Res. 1987;47:4915. [PubMed] [Google Scholar]
  • 4.Fearon ER, Itaya T, Hunt B, Vogelstein V, Frost P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 1988;48:2975. [PubMed] [Google Scholar]
  • 5.Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52:456. doi: 10.1016/0042-6822(73)90341-3. [DOI] [PubMed] [Google Scholar]
  • 6.Itaya T, Hunt B, Frost P. Retention of immunogenicity after X-irradiation of mouse colon cells expressing the transfected influenza virus hemagglutinin gene. Clin Immunol Immunother. 1989;28:248. doi: 10.1007/BF00205233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Janeway CA, Carding S, Jones B, Murray J, Portoles P, Rasmussen R, Rojo J, Saizawa K, West J, Bottomly K. CD4+ T cells: specificity and functions. Immunol Rev. 1988;101:39. doi: 10.1111/j.1600-065x.1988.tb00732.x. [DOI] [PubMed] [Google Scholar]
  • 8.Janis E, Kaufmann SE, Schwartz RH, Pardoll DM. Activation of gamma/delta T cells in the primary immune response to mycobacterium tuberculosis. Science. 1989;244:713. doi: 10.1126/science.2524098. [DOI] [PubMed] [Google Scholar]
  • 9.Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol. 1988;18:97. doi: 10.1002/eji.1830180115. [DOI] [PubMed] [Google Scholar]
  • 10.Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorgenicity of interleukin 2-dependent helper T cells transfected with the IL-2 gene. J Exp Med. 1989;169:13. doi: 10.1084/jem.169.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Keene JA, Foreman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med. 1982;155:768. doi: 10.1084/jem.155.3.768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Kerbel RS, Waghorne C, Man MD, Elliott B, Breitman ML. Alterations of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. Proc Natl Acad Sci USA. 1987;84:1263. doi: 10.1073/pnas.84.5.1263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lake P, Mitchinson NA. Associative control of the immune response to cell surface antigens. Immunol Commun. 1976;5:795. doi: 10.3109/08820137609047620. [DOI] [PubMed] [Google Scholar]
  • 14.Reed L, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg. 1938;27:493. [Google Scholar]
  • 15.Sambrook J, Rogers L, White J, Gething MJ. Lines of BPV-transformed mouse cells that constitutively express influenza virus hemagglutinin. EMBO J. 1985;4:91. doi: 10.1002/j.1460-2075.1985.tb02322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Schackert HK, Itaya T, Schackert G, Fearon ER, Vogelstein B, Frost P. Systemic immunity against a murine colon tumor (CT-26) produced by immunization with syngeneic cells expressing a transfected viral gene product. Int J Cancer. 1989;43:812. doi: 10.1002/ijc.2910430514. [DOI] [PubMed] [Google Scholar]
  • 17.Simcik W, Frost P, LeGrue SJ. Immunologic characteristics of immunogenic variants induced in the MCA-F murine fibrosarcoma using 1-methyl-3-nitro-1-nitrosoguanidine, 5-aza-2′-deoxycytidine or ultraviolet light. Cancer Res. 1989;49:4192. [PubMed] [Google Scholar]
  • 18.Swain SL. T cell subsets and the recognition of MHC class. Immunol Rev. 1983;74:129. doi: 10.1111/j.1600-065x.1983.tb01087.x. [DOI] [PubMed] [Google Scholar]
  • 19.Tanaka K, Yoshioka T, Bieberich C, Jay G. Role of the major histocompatibility complex class I antigens in tumor growth and development. Annu Rev Immunol. 1987;6:359. doi: 10.1146/annurev.iy.06.040188.002043. [DOI] [PubMed] [Google Scholar]
  • 20.Tanaka K, Yoshioka T, Bieberich C, Jay G. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol. 1988;6:359. doi: 10.1146/annurev.iy.06.040188.002043. [DOI] [PubMed] [Google Scholar]
  • 21.Wiltrout RH, Frost P, Cummings GD. Isotope release cytotoxicity assay with the use of111indium: advantage over chromium-51 in long term assays. J Natl Cancer Inst. 1978;49:169. doi: 10.1093/jnci/61.1.183. [DOI] [PubMed] [Google Scholar]
  • 22.Wraith DC. The recognition of influenza A virus-infected cells by cytotoxic T lymphocytes. Immunol Today. 1987;8:239. doi: 10.1016/0167-5699(87)90174-5. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES